StockData
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Denali Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.04+0.43 (+2.44%)

Close on Oct 19, 2026

Market cap
$3.38B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026During market hours$3.60M$-0.68–
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026During market hours–$-0.69–
Q4 FY2025
Ended Dec 31, 2025
Feb 26, 2026During market hours–$-0.73–
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025During market hours–––
Q2 FY2025
Ended Jun 30, 2025
Aug 11, 2025During market hours–––
Q1 FY2025
Ended Mar 31, 2025
May 6, 2025During market hours–$-0.78–
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025During market hours–––
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024During market hours–$-0.63–
Q2 FY2024
Ended Jun 30, 2024
Aug 1, 2024Before market open–$-0.59–
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024During market hours–$-0.68–
Q4 FY2023
Ended Dec 31, 2023
Feb 27, 2024Before market open–$-0.86–

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
AVLAYAH net product revenuethird-quarter 2026$10.00M to $12.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Denali Therapeutics filed with the SEC